Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cyclerion Therapeutics Inc (CYCN)

Cyclerion Therapeutics Inc (CYCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,618
  • Shares Outstanding, K 2,710
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,260 K
  • 60-Month Beta 1.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.73
Trade CYCN with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.80 +14.94%
on 04/11/24
3.98 -19.14%
on 04/04/24
-0.03 (-0.98%)
since 03/15/24
3-Month
2.54 +26.70%
on 01/26/24
4.00 -19.55%
on 02/09/24
-0.58 (-15.31%)
since 01/17/24
52-Week
1.75 +83.89%
on 11/28/23
7.00 -54.03%
on 04/19/23
-3.66 (-53.20%)
since 04/17/23

Most Recent Stories

More News
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates

Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

CYCN : 3.22 (+1.20%)
ADMA : 6.04 (-1.95%)
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like...

CYCN : 3.22 (+1.20%)
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors

Renowned neuroscience leader to further long-term clinical research strategy and external collaborations...

CYCN : 3.22 (+1.20%)
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients ...

CYCN : 3.22 (+1.20%)
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa,...

CYCN : 3.22 (+1.20%)
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for...

CYCN : 3.22 (+1.20%)
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood...

CYCN : 3.22 (+1.20%)
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

Topline results to be shared during the clinical trial update platform session CHOP preclinical data demonstrates CY6463-induced functional improvement in...

CYCN : 3.22 (+1.20%)
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Characterizing the novel neuropharmacology of CY6463’s NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing,...

CYCN : 3.22 (+1.20%)
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 ...

CYCN : 3.22 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. The company's product pipeline consists of Olinciguat, Praliciguat and IW-6463 which are in...

See More

Key Turning Points

3rd Resistance Point 3.61
2nd Resistance Point 3.53
1st Resistance Point 3.38
Last Price 3.22
1st Support Level 3.14
2nd Support Level 3.06
3rd Support Level 2.90

See More

52-Week High 7.00
Fibonacci 61.8% 4.99
Fibonacci 50% 4.38
Fibonacci 38.2% 3.76
Last Price 3.22
52-Week Low 1.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar